← Eichor
Study identifier: NCT02419365 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

International Primary Ciliary Dyskinesia (PCD) Registry

Condition: Primary Ciliary Dyskinesia (PCD)  ·  Sponsor: University Hospital Muenster

PhaseN/A
Planned participants2000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The purpose of the international prospective PCD Patient Registry is to systematically measure, survey and compare different aspects of PCD manifestation, course and treatment, to provide data for epidemiological research and to identify special patient groups suitable for multi-center trials. This International PCD Registry is also part of the European Reference Network ERN-LUNG. We follow the recommendations of the EU Expert Committee on Rare Diseases (EUCERD), which recommend an international interoperability of registries and databases to pool and exchange knowledge and data on rare diseases.

This description comes directly from the study's public registry record.

Talk to the study team

Petra Pennekamp, PhD  ·  +4925183  ·  petra.pennekamp@ukmuenster.de

Simone Helms  ·  +4925183  ·  Simone.Helms@ukmuenster.de

Always discuss trial participation with your own doctor first.

Locations (2)

University Hospital MünsterMünster, North Rhine-Westphalia, GermanyRecruiting
University Hospital Muenster, Department of General PediatricsMünster, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02419365